Skip to content
Clinical Trials – home
PortugalBack to Portugal

Clinical trials in Montijo – page 36

673 clinical trials in Montijo, Portugal. Every trial is listed in the EU Clinical Trials Register and updated daily.

PortugalOur site in PortugalEnsaios-Clinicos.pt(opens in a new tab)
Montijo at a glance
673
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

673 trials in Montijo

Open in trial search

Study on Palbociclib and Endocrine Therapy for Patients with HR+/HER2- Early Breast Cancer

InvestigationalNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Palbociclib
  • Sponsor:ABCSG GmbH

Study on Fenebrutinib and Teriflunomide for Adults with Relapsing Multiple Sclerosis

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years
  • Substances:Fenebrutinib
  • Sponsor:F. Hoffmann-La Roche AG

Study Comparing Lazertinib and Subcutaneous Amivantamab with Intravenous Amivantamab for Patients with EGFR-mutated Advanced or Metastatic Non-small Cell Lung Cancer

InvestigationalNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Amivantamab
  • Sponsor:Janssen Cilag International

Safety and Efficacy Study of Efgartigimod PH20 Subcutaneous in Adults with Primary Immune Thrombocytopenia

InvestigationalNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx

Study on Long-Term Safety and Effectiveness of Ofatumumab for Patients with Relapsing Multiple Sclerosis

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years
  • Substances:Ofatumumab
  • Sponsor:Novartis Pharma AG

Giant cell arteritis

Not recruiting

Study on the Safety and Effectiveness of Upadacitinib and Prednisolone in Patients with Giant Cell Arteritis

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Prednisolone
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study of Zolbetuximab and CAPOX for Patients with Advanced Gastric or Gastroesophageal Junction Cancer

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:Astellas Pharma Global Development Inc.

Plasma cell myeloma

Not recruiting

Study comparing iberdomide, daratumumab and dexamethasone versus daratumumab, bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Celgene Corp.

Study Comparing the Effectiveness and Safety of Macitentan 75 mg and 10 mg for Patients with Pulmonary Arterial Hypertension

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Macitentan
  • Sponsor:Actelion Pharmaceuticals Ltd.

Study Comparing XL092 and Atezolizumab with Regorafenib for Patients with Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Exelixis Inc.

Study of Subcutaneous Nivolumab for Patients with Previously Treated Advanced or Metastatic Clear Cell Kidney Cancer

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Study on the Effectiveness and Safety of Fenfluramine Hydrochloride for Patients with CDKL5 Deficiency Disorder

Registered drug
Countries:PortugalPortugal
  • Participants:0–17 years · 18–64 years
  • Substances:Fenfluramine Hydrochloride
  • Sponsor:Zogenix International Limited

Other cities in Portugal

The busiest research cities in the country

All 48 cities in Portugal

Clinical research in Montijo

What the registry says about research in the country

01 Cardiovascular Diseases

Montijo hosts a focused research effort on cardiovascular diseases, with two active recruiting trials at a single site led by a local investigator.

  • Evaluation of zilebesiran in patients with uncontrolled hypertension and established or high‑risk cardiovascular disease
  • Assessment of the antibody combination REGN7508 and REGN9933 for preventing ischemic stroke and systemic embolism in atrial fibrillation patients
  • Investigation of major bleeding risk associated with the REGN antibody therapy
  • Inclusion of participants with atrial fibrillation, established cardiovascular disease, high cardiovascular risk and hypertension

These studies aim to improve outcomes by testing novel therapies and safety profiles, positioning Montijo as a niche hub for cardiovascular innovation in Portugal.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.